LJPC

LJPC Articles

Despite the wild ride the markets have taken, the faith of insiders certainly has not been shaken. It is indeed a positive to see insiders buying shares at current levels.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include CenturyLink, Gold Fields, Papa John's, Priceline, SolarCity, Tesla Motors and Unisys.
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce,com, Tesla and Yelp.
La Jolla Pharmaceuticals has announced the pricing of an underwritten offering of 2.55 million shares of its common stock.
The overwhelming cascade of insider buyers should come as no surprise, given the huge drops in the market over the past week and a half.
La Jolla Pharmaceutical has received an analyst call that implies a potential doubling of its shares.
One would expect that insiders looking to add to their positions would wait for a downturn in the market. That wasn’t the case this past week.
ThinkstockStocks seem to be migrating from a tired bull market phase into a phase of volatility. It is also a phase where broad-based upside might not be an automatic assumption going forward. Many...
These are the top analyst upgrades, downgrades and initiations from Wall Street analysts on Monday, August 4, 2014. They include Alcatel-Lucent, AEP, Chubb, Chevron, Halcon and Noble.
La Jolla Pharmaceutical shares surged after the micro-cap biotech said late Monday that its study for a chronic kidney disease treatment showed a statistically significant improvement.
We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering.   We published a full...
La Jolla Pharmaceutical Company (NASDAQ: LJPC) has been more than just a troubled biotech.  It has even been considered an at-risk entity by some traders after it had been down more than 90% at one...
Biogen Idec (NASDAQ: BIIB) is sliding marginally despite reported earnings today that showed a 23% increase in earnings riding on sales growth on Avonex and Rituxan. The earnings beat estimates and...